---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-091625"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2026-08-06T11:12:23+00:00"
generated_at: "2026-08-06T11:15:14.659759+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ironwood raises FY2026 guidance after strong Q2; LINZESS sales up 44% YTD

## Summary
- Q2 total revenue $113M, GAAP net income $51M ($0.31 diluted EPS), adjusted EBITDA $83M.
- LINZESS U.S. net sales Q2 $282M, YTD $555M (+44% YoY).
- FY2026 guidance raised: LINZESS net sales $1.15-1.20B, total revenue $460-485M, adjusted EBITDA >$310M.
- Repaid $200M convertible notes with cash on hand; balance sheet strengthening.
- Confirmatory Phase 3 STARS-2 trial of apraglutide in SBS-IF actively recruiting.

## SEC filing metadata
- accession: 0001104659-26-091625
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2026-08-06T11:12:23+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465926091625/0001104659-26-091625-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465926091625/tm2622244d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-091625
- JSON: https://secwatch.observer/filing/0001104659-26-091625.json
- Plain text: https://secwatch.observer/filing/0001104659-26-091625.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.